Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$76.09
0.290.38%
At close: -
$76.09
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Corcept Therapeutics Analyst Ratings and Price Targets | NASDAQ:CORT | Benzinga
Corcept Therapeutics Inc has a consensus price target of $92 based on the ratings of 7 analysts. The high is $150 issued by Truist Securities on March 31, 2025. The low is $22 issued by Jefferies on February 15, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and Canaccord Genuity on May 6, 2025, April 3, 2025, and April 1, 2025, respectively. With an average price target of $139.33 between HC Wainwright & Co., Piper Sandler, and Canaccord Genuity, there's an implied 83.12% upside for Corcept Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Canaccord Genuity
Truist Securities
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Corcept Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2025 | Buy Now | 90.56% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $150 → $145 | Maintains | Buy | Get Alert |
| 04/03/2025 | Buy Now | 72.16% | Piper Sandler | David Amsellem73% | $128 → $131 | Maintains | Overweight | Get Alert |
| 04/01/2025 | Buy Now | 86.62% | Canaccord Genuity | Edward Nash67% | $130 → $142 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 97.13% | Truist Securities | Joon Lee77% | $76 → $150 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 97.13% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $115 → $150 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 2.51% | Piper Sandler | David Amsellem73% | $67 → $78 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 51.14% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $115 → $115 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 51.14% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $80 → $115 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 5.14% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2025 | Buy Now | 70.85% | Canaccord Genuity | Edward Nash67% | $78 → $130 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 5.14% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 5.14% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $45 → $80 | Maintains | Buy | Get Alert |
| 09/30/2024 | Buy Now | -0.12% | Truist Securities | Joon Lee77% | $65 → $76 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | -11.95% | Piper Sandler | David Amsellem73% | $38 → $67 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | 2.51% | Canaccord Genuity | Edward Nash67% | $38 → $78 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | -50.06% | Canaccord Genuity | Edward Nash67% | $38 → $38 | Maintains | Buy | Get Alert |
| 07/30/2024 | Buy Now | -50.06% | Piper Sandler | David Amsellem73% | $35 → $38 | Maintains | Overweight | Get Alert |
| 07/30/2024 | Buy Now | -40.86% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $40 → $45 | Maintains | Buy | Get Alert |
| 07/01/2024 | Buy Now | -54% | Piper Sandler | David Amsellem73% | $35 → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | -14.57% | Truist Securities | Joon Lee77% | $65 → $65 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | -14.57% | Truist Securities | Joon Lee77% | $44 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | -47.43% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | -47.43% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $38 → $40 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -42.17% | Truist Securities | Joon Lee77% | $42 → $44 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | -50.06% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | -44.8% | Truist Securities | Joon Lee77% | $36 → $42 | Maintains | Buy | Get Alert |
| 01/02/2024 | Buy Now | -63.2% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $34 → $28 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -50.06% | Canaccord Genuity | Edward Nash67% | $37 → $38 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | -50.06% | Truist Securities | Joon Lee77% | $29 → $38 | Upgrade | Hold → Buy | Get Alert |
| 11/02/2023 | Buy Now | -55.32% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $32 → $34 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | -61.89% | Truist Securities | Joon Lee77% | → $29 | Reiterates | Hold → Hold | Get Alert |
| 08/25/2023 | Buy Now | -54% | Canaccord Genuity | Edward Nash67% | $34 → $35 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -59.26% | Piper Sandler | David Amsellem73% | $27 → $31 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -61.89% | Truist Securities | Gregory Fraser63% | $26 → $29 | Maintains | Hold | Get Alert |
| 08/03/2023 | Buy Now | -57.94% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $30 → $32 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | -65.83% | Truist Securities | Gregory Fraser63% | $28 → $26 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | -60.57% | HC Wainwright & Co. | Swayampakula Ramakanth51% | → $30 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | -67.14% | SVB Leerink | Roanna Ruiz36% | → $25 | Initiates | → Market Perform | Get Alert |
| 04/04/2023 | Buy Now | -64.52% | Piper Sandler | David Amsellem73% | → $27 | Initiates | → Overweight | Get Alert |
| 03/08/2023 | Buy Now | -57.94% | Canaccord Genuity | Edward Nash67% | $33 → $32 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | -60.57% | HC Wainwright & Co. | Swayampakula Ramakanth51% | → $30 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | -71.09% | Jefferies | Dennis Ding16% | $35 → $22 | Downgrade | Buy → Hold | Get Alert |
| 12/09/2022 | Buy Now | -60.57% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $33 → $30 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | -63.2% | Truist Securities | Gregory Fraser63% | $30 → $28 | Maintains | Hold | Get Alert |
| 08/04/2022 | Buy Now | -56.63% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $29 → $33 | Maintains | Buy | Get Alert |
| 08/01/2022 | Buy Now | -60.57% | Truist Securities | Gregory Fraser63% | → $30 | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Corcept Therapeutics (CORT) stock?
The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by HC Wainwright & Co. on May 6, 2025. The analyst firm set a price target for $145.00 expecting CORT to rise to within 12 months (a possible 90.56% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corcept Therapeutics (CORT)?
The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by HC Wainwright & Co., and Corcept Therapeutics maintained their buy rating.
When was the last upgrade for Corcept Therapeutics (CORT)?
The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.
When was the last downgrade for Corcept Therapeutics (CORT)?
The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Corcept Therapeutics (CORT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.
Is the Analyst Rating Corcept Therapeutics (CORT) correct?
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $150.00 to $145.00. The current price Corcept Therapeutics (CORT) is trading at is $76.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
